PATENT CLAIM ANALYSIS

Application Number: 15767371
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "337000"]

Abstract:
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are antagonists of leukotriene B 4  receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B 4  receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension. Non-alcoholic fatty liver disease/nonalcoholic steatoepatitis metabolic syndrome, atherosclerosis, and cancer.

Claim (Index 11):
The compound according to  claim 1  wherein A is selected from the group consisting of: pyridine, thiazole, thiadiazole, and pyrazole, wherein pyridine, thiazole, thiadiazole, and pyrazole are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.67241
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15768097', '15769079', '13614534', '13140997', '16334391']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.827865334622226
- 35 USC 102 Novelty (BERT): 0.6194408990501638
- Combined Prediction Score: 0.8070228910650199
- Mean Citation Score: 413.685834
- Max Citation Score: 580.38086
- Similarity Product: 522.9430593459856

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test